The association between inflammation and malignancies is being recognized. In this study, we assessed the use of preoperative neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) in predicting cancer-specific survival (CSS) and inguinal node involvement in patients with carcinoma penis.
Intravesical Bacillus Calmette-Guérin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer.
To explore patient perspectives of muscle-invasive bladder cancer (MIBC) on how the health care team and their social network can support them during their cancer trajectory. Sixteen semi-structured interviews were conducted with MIBC survivors who underwent radical cystectomies at Ghent University Hospital.
(UroToday.com) In the Plenary session of the Société Internationale D’Urologie (SIU) 2021 annual meeting, Dr. Mark Emberton presented the SIU-Mostafa M. Elhilali Award Lecture focusing on his reflections on the evolution of prostate cancer treatment.
Blue light cystoscopy (BLC) for the management of non-muscle invasive bladder cancer (NMIBC) is an evidence- and guideline-supported intervention that has been shown to increase cancer detection and decrease recurrence. That considered, there are practical limitations to the use of BLC including the availability of technology and peri-operative patient workflow that includes catheterization and instillation […]
IMPORTANCE Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing to a potential decrease in the tissuebased expression of the SARS-CoV-2 coreceptor transmembrane protease, serine 2 (TMPRSS2).
San Francisco, CA (UroToday.com) — Men being treated for prostate cancer with abiraterone have a better quality of life than those treated with docetaxel. This is according to results from an analysis of quality of life data from the STAMPEDE trial, which was published yesterday in the Journal of Clinical Oncology.
– 100% of Patients Evaluable for Efficacy (N=9) Achieved Complete Response (CR) at the Initial 3-Month Timepoint –– For Patients That Reached Additional Timepoints, 100% (N=6) Have Also Maintained a CR Through 6 Months and 100% (N=3) at the 9-Month Assessment –– Treatment Related Adverse Events (AEs) Were Limited to Transient Grade 1-2 Local Genitourinary […]
The year 2021 marks the 50th anniversary of the National Cancer Act of 1971, which designated defeating cancer a national priority and allocated substantial resources to the National Cancer Institute, including a budget bypassing congressional approval.1 Subsequently, the National Cancer Institute’s annual budget increased 25-fold, from $227 million in 1971 to $1 billion in 1980 and […]
(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Wassim Kassouf discussing DDR mutations and response to chemotherapy. For context, Dr. Kassouf noted that for metastatic muscle-invasive bladder cancer, 25% of patients do not response to first-line cisplatin-based chemotherapy, and even among responders […]
